Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Autor: | Kenneth J. O'Byrne, Jaafar Bennouna, Vera Hirsh, Kazuhiko Nakagawa, Eng Huat Tan, Yi-Long Wu, Tony Mok, Shun Lu, Li Zhang, James Chih-Hsin Yang, Martin Schuler, Toyoaki Hida, Hiroshi Tanaka, Terufumi Kato, Keunchil Park, Denis Moro Sibilot, Michael Boyer, Nobuyuki Yamamoto, Angela Märten, Caicun Zhou, W. Tang, Luis Paz-Ares |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Afatinib medicine.medical_treatment Medizin Platinum Compounds 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Osimertinib Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Aged Neoplasm Staging Retrospective Studies Aged 80 and over Chemotherapy Acrylamides Aniline Compounds biology business.industry Middle Aged medicine.disease Survival Analysis Discontinuation ErbB Receptors 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Mutation biology.protein Female Non small cell business Tyrosine kinase medicine.drug |
Zdroj: | Lung cancer (Amsterdam, Netherlands). 132 |
ISSN: | 1872-8332 |
Popis: | Objectives With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (Del19/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib. Methods Post-progression therapy data were prospectively collected during follow-up. Molecular testing of tumours at progression/discontinuation of afatinib was not mandatory. Duration of subsequent therapies, and survival following osimertinib, were calculated with Kaplan–Meier estimates. Results Among 553 patients who discontinued first-line afatinib, second-, third- and fourth-line therapy was administered in 394 (71%), 265 (48%), and 156 (28%) patients. The most common post-progression therapy was platinum-based chemotherapy (46%). Thirty-seven patients received subsequent osimertinib, 10 as second-line treatment. Median progression-free survival on afatinib in these 37 patients was 21.9 months. Median duration of osimertinib therapy was 20.2 months; median overall survival was not reached after a median follow-up of 4.7 years. Conclusions Most patients treated with first-line afatinib received subsequent therapy. Although limited by sample size, enrichment, and a retrospective nature, data from patients who received sequential afatinib and osimertinib are encouraging, warranting further investigation. |
Databáze: | OpenAIRE |
Externí odkaz: |